Sadeghi R, Tabasi K T, Bazaz S M M, Kakhki V R D, Massoom A F, Gholami H, Zakavi S R
Nuclear Medicine Research Center, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Ebn Sina Street, Mashhad, Iran.
Nuklearmedizin. 2011;50(3):107-15. doi: 10.3413/nukmed-0339-10-07. Epub 2011 Jan 25.
Sentinel node (SN) biopsy is becoming a standard procedure in the management of several malignancies. Several groups have evaluated the feasibility and value of this procedure in prostate cancer patients. In the current meta-analysis, we comprehensively and quantitatively summarized the results of these studies.
Several databases including Medline, SCOPUS, Google Scholar, Ovid, Springer, and Science direct were systematically searched for the relevant studies regarding SL biopsy in the prostate cancer ("prostate" AND "sentinel" as search keywords). The outcomes of interest were sensitivity and detection rate of the procedure.
For detection rate and sensitivity 21 and 16 studies met the criteria of inclusion respectively. Pooled detection rate was 93.8% (95% CI 89-96.6%). Cochrane Q value was 216.077 (I2 = 89.81% and p < 0.001). Pooled sensitivity was 94% (95% CI 91-96%). Cochrane Q value was 14.12 (I2 = 0.0 and p = 0.516).
SL biopsy can prevent unnecessary pelvic lymph node dissection in prostate cancer patients. This procedure is feasible with low false negative rate and high detection rate.
前哨淋巴结活检正成为多种恶性肿瘤治疗中的标准程序。多个研究小组已评估了该程序在前列腺癌患者中的可行性和价值。在当前的荟萃分析中，我们全面且定量地总结了这些研究的结果。
系统检索了多个数据库，包括Medline、SCOPUS、谷歌学术、Ovid、施普林格和科学Direct，以查找有关前列腺癌中前哨淋巴结活检的相关研究（以“前列腺”和“前哨”作为检索关键词）。感兴趣的结果是该程序的敏感性和检出率。
分别有21项和16项研究符合检出率和敏感性的纳入标准。合并检出率为93.8%（95%可信区间89 - 96.6%）。Cochrane Q值为216.077（I² = 89.81%，p < 0.001）。合并敏感性为94%（95%可信区间91 - 96%）。Cochrane Q值为14.12（I² = 0.0，p = 0.516）。
前哨淋巴结活检可避免前列腺癌患者进行不必要的盆腔淋巴结清扫。该程序可行，假阴性率低且检出率高。
